140 related articles for article (PubMed ID: 38648855)
21. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro TB; Buss L; Wayant C; Nobre MRC
PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
[TBL] [Abstract][Full Text] [Related]
22. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
[TBL] [Abstract][Full Text] [Related]
23. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
[TBL] [Abstract][Full Text] [Related]
24. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
25. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Neumann PJ; Crummer E; Chambers JD; Tunis SR
Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
[TBL] [Abstract][Full Text] [Related]
26. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Naci H; Zhang Y; Woloshin S; Guan X; Xu Z; Wagner AK
Lancet Oncol; 2024 Jun; 25(6):760-769. PubMed ID: 38754451
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
29. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
30. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.
Luo X; Du X; Huang L; Guo Q; Lv X; Wang C; Liu H; Zhou Y; Xue X; Li Z; Liu J; Chow SC; Yang Y
EClinicalMedicine; 2023 Sep; 63():102177. PubMed ID: 37662522
[TBL] [Abstract][Full Text] [Related]
31. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
Kern KA
J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
33. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.
Rittberg R; Czaykowski P; Niraula S
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254
[TBL] [Abstract][Full Text] [Related]
35. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.
Michaeli DT; Michaeli T; Albers S; Michaeli JC
BMJ Evid Based Med; 2024 May; ():. PubMed ID: 38760158
[TBL] [Abstract][Full Text] [Related]
36. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
Pregelj L; Hine DC; Kesselheim AS; Darrow JJ
Clin Pharmacol Ther; 2021 Oct; 110(4):1018-1024. PubMed ID: 34048058
[TBL] [Abstract][Full Text] [Related]
37. Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.
Herink MC; Johnston K; Breninger K; Wu E; Irwin AN
Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287447
[TBL] [Abstract][Full Text] [Related]
38. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022.
Luo X; Qian F; Yang L; Li Y; Yang Y
Drug Discov Today; 2022 Dec; 27(12):103370. PubMed ID: 36154876
[TBL] [Abstract][Full Text] [Related]
40. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
